Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
19.50
-0.05 (-0.26%)
At close: May 16, 2025, 4:00 PM
19.12
-0.38 (-1.95%)
After-hours: May 16, 2025, 7:57 PM EDT
Outset Medical Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Outset Medical stock ranges from a low of $14 to a high of $45. The average analyst price target of $29.5 forecasts a 51.28% increase in the stock price over the next year.
Price Target: $29.50 (+51.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outset Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | -28.21% | May 8, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $45 | Hold | Reiterates | $45 | +130.77% | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $90 → $45 | Buy → Hold | Downgrades | $90 → $45 | +130.77% | Aug 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $135 → $45 | Strong Buy | Maintains | $135 → $45 | +130.77% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $75 → $90 | Hold → Buy | Upgrades | $75 → $90 | +361.54% | Jun 21, 2024 |
Financial Forecast
Revenue This Year
125.53M
from 113.69M
Increased by 10.42%
Revenue Next Year
140.16M
from 125.53M
Increased by 11.65%
EPS This Year
-4.48
from -36.95
EPS Next Year
-3.93
from -4.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 128.7M | 147.0M | 169.9M | ||
| Avg | 125.5M | 140.2M | 156.9M | ||
| Low | 117.8M | 129.9M | 144.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.2% | 17.1% | 21.2% | ||
| Avg | 10.4% | 11.7% | 12.0% | ||
| Low | 3.6% | 3.4% | 2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.47 | -2.32 | -1.45 | ||
| Avg | -4.48 | -3.93 | -3.77 | ||
| Low | -7.82 | -8.33 | -7.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.